Pharmaceutical Technology

MAY 11, 2023

Results published in Nature for a personalised pancreatic cancer vaccine that uses neoantigens from patients’ tumours have lent further support to early positive signals. The vaccine, developed by BioNTech, led to half of the patients with pancreatic cancer in the Phase I trial remaining cancer-free 18 months later.

RNA 345

RNA Vaccination Vaccine Trials 345

AuroBlog - Aurous Healthcare Clinical Trials blog

MAY 1, 2024

Scientists have developed a vaccine against a notorious drug-resistant superbug, targeting molecules on its surface that are also found on other bacteria and fungi.

Vaccination 181

Vaccination Vaccine Bacteria Drugs 181

Pharmaceutical Technology

FEBRUARY 3, 2023

Only a few weeks into the new year, the prospect of getting a successful advanced HIV vaccine shrank after the discontinuation of yet another late-stage trial. On January 18, Janssen, a Johnson & Johnson (J&J) subsidiary, stated that its vaccine was not effective in preventing HIV infections.

Vaccination 293

Vaccination Vaccine Antibody Trials 293

Pharmaceutical Technology

APRIL 14, 2023

Ghana’s Food and Drug Authority (FDA) has approved R21/Matrix-M malaria vaccine in children aged 5 to 36 months, marking the first regulatory clearance for the University of Oxford-developed vaccine in any country in the world. Children between the ages of five and 36 months are at highest risk of death from malaria.

Vaccination 279

Vaccination Vaccine Manufacturing Containment 279

AuroBlog - Aurous Healthcare Clinical Trials blog

OCTOBER 8, 2023

The World Health Organization has approved a new vaccine that scientists argue will be a game-changer in the fight against malaria, which kills half a million people in Africa every year.

Vaccination 199

Vaccination Vaccine Scientist Trials 199

pharmaphorum

MAY 2, 2024

A personalised vaccine for the aggressive brain cancer glioblastoma developed has shown encouraging signs of efficacy in its first human trial.

RNA 101

RNA Vaccination Vaccine Trials 101

Pharmaceutical Technology

MAY 18, 2023

International non-profit research organisation IAVI and Zendal Group’s subsidiary Biofabri have signed an expanded deal to develop MTBVAC, a tuberculosis (TB) vaccine candidate. The organisation and the company initially collaborated in 2021 to advance the vaccine candidate into efficacy trials.

Vaccination 130

Vaccination Vaccine Development Trials 130

Pharmaceutical Technology

MARCH 14, 2023

The National Health Surveillance Agency (ANVISA) in Brazil has granted approval for Takeda ’s dengue virus vaccine candidate, Qdenga (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003). The vaccine has received approval for preventing dengue disease in people aged four years to 60 years.

Vaccination 286

Vaccination Vaccine Clinical Trials Clinical Trials 286

Pharmaceutical Technology

SEPTEMBER 7, 2022

Indian company Bharat Biotech International has secured approval from Central Drugs Standard Control Organisation (CDSCO) under Restricted Use in Emergency Situation for its intranasal Covid-19 vaccine, iNCOVACC (BBV154), for usage in people aged 18 years and older. It is formulated to permit intranasal delivery via nasal drops.

Vaccination 263

Vaccination Vaccine Clinical Trials Clinical Trials 263

Pharmaceutical Technology

FEBRUARY 7, 2023

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Takeda ’s dengue virus vaccine candidate, Qdenga (Dengue Tetravalent Vaccine [Live, Attenuated]). The vaccine candidate has been approved for active immunisation against the infection in people from four years of age.

Vaccination 264

Vaccination Vaccine Genetics Trials 264

Bio Pharma Dive

SEPTEMBER 17, 2020

The biotech, among the furthest along in coronavirus vaccine development, is the first developer to share the so-called study protocol of its large Phase 3 trial.

Vaccination 331

Vaccination Vaccine Trials Development 331

Pharmaceutical Technology

OCTOBER 6, 2022

from the US National Institutes of Health (NIH) unit National Institute of Allergy and Infectious Diseases (NIAID) to develop a prophylactic intranasal vaccine against Neisseria gonorrhoeae (NG). Leveraging its outer membrane vesicles (OMV) platform technology, Intravacc will develop the vaccine.

Vaccination 147

Vaccination Vaccine Development Bacterium 147

Pharmaceutical Technology

JUNE 9, 2023

5+delta) protein vaccine (Sf9 cell). This marks the world’s first Covid-19 vaccine approved for emergency use against XBB descendent lineages of SARS-CoV-2. The vaccine has been developed by WestVac Biopharma along with the West China Medical Center and Sichuan University. recombinant Covid-19 trivalent (XBB.1.5+BA.5+delta)

Vaccination 269

Vaccination Vaccine HR Protein 269

Drug Discovery World

NOVEMBER 24, 2023

The University of Queensland’s re-engineered clamp platform has produced a vaccine that is equally safe and virus-neutralising as an approved Covid vaccine considered among the best in its class. The Clamp2 trial group showed a 2.5-fold million to continue development for use in the global response to future disease outbreaks.

Clinical Trials 110

Clinical Trials Clinical Trials Engineer Vaccination 110

Pharmaceutical Technology

MARCH 9, 2023

Oxford, UK-based vaccine company SpyBiotech is planning to start dosing subjects for a Phase I trial of its lead vaccine candidate against human cytomegalovirus (HCMV) infection in H2 2023, says chief scientific officer (CSO) Sumi Biswas. The Phase I trial will test three doses of the vaccine, says Biswas.

Vaccination 162

Vaccination Vaccine Trials Protein 162

Pharmaceutical Technology

DECEMBER 7, 2022

Health Canada has granted approval for a supplement to a New Drug Submission (sNDS) of Novavax ’s Covid-19 vaccine (Recombinant protein, Adjuvanted), Nuvaxovid (NVX-CoV2373), for use in adolescents aged 12 to 17 years. The trial is designed to analyse the safety and effectiveness of the vaccine.

Vaccination 264

Vaccination Vaccine Protein Clinical Trials 264

Pharmaceutical Technology

JANUARY 13, 2023

The Biomedical Advanced Research and Development Authority (BARDA) has awarded a multi-year contract to the Sabin Vaccine Institute for developing and producing single-dose vaccine candidates for Ebola Sudan and Marburg virus diseases. Currently, there are no licensed vaccines against these viruses.

Vaccination 246

Vaccination Vaccine Clinical Trials Clinical Trials 246

Pharmaceutical Technology

NOVEMBER 24, 2022

South African bio-pharmaceutical firm Biovac and the International Vaccine Institute (IVI) in South Korea have signed a licencing and technology transfer agreement for developing and manufacturing an oral cholera vaccine (OCV).

Vaccination 147

Vaccination Vaccine Development Manufacturing 147

XTalks

FEBRUARY 19, 2024

Moderna has been testing an experimental mRNA vaccine aimed at combating the human cytomegalovirus (CMV), which poses significant health risks to newborns and immunocompromised patients. The team used the data and patient samples from a gB/MF59 Phase II trial in adolescent girls as a benchmark to assess the new mRNA-based vaccine.

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

BioSpace

MAY 12, 2024

The race is on to develop therapeutic cancer vaccines that could give immunotherapies an edge, and late-stage trials could soon provide more-robust data about candidates’ efficacy and safety.

Vaccination 126

Vaccination Vaccine Trials Development 126

Pharmaceutical Technology

DECEMBER 11, 2022

The US Food and Drug Administration (FDA) has granted Fast Track designation for Pfizer and BioNTech’s messenger ribonucleic acid (mRNA)-based combination vaccine candidate against Covid-19 and influenza. The vaccine is intended to prevent two respiratory ailments through a single injection. 5 Omicron sublineages spike proteins.

Vaccination 289

Vaccination Vaccine Gene Therapy Gene 289

AuroBlog - Aurous Healthcare Clinical Trials blog

JANUARY 22, 2024

The Indian Institute of Science (IISc) is now developing a heat-tolerant vaccine that can offer protection against different strains of SARS-CoV-2 – both current and future variants. The research […]

Vaccination 138

Vaccination Vaccine Development Research 138

Pharmaceutical Technology

OCTOBER 31, 2022

After decades of setbacks, the respiratory syncytial virus (RSV) vaccine field has bounced back with positive Phase III trial results in older adults. There are currently five players in the race, with vaccines in Phase III of development from GlaxoSmithKline (GSK) , Pfizer , Johnson & Johnson , Moderna and Bavarian Nordic.

Vaccination 338

Vaccination Vaccine Marketing Trials 338

Pharmaceutical Technology

OCTOBER 26, 2022

SK bioscience has signed a new collaboration agreement with the Coalition for Epidemic Preparedness Innovations (CEPI) to develop messenger ribonucleic acid (mRNA) vaccines for infectious diseases. The company has obtained the newest vaccine platform technologies such as bacterial culture, cell culture and genetic recombination.

Vaccination 130

Vaccination Vaccine Development Gene Therapy 130

Drug Discovery World

APRIL 15, 2024

Naobios has signed a partnership agreement with Sumagen, a Korean-Canadian biotechnology company developing an HIV-1 vaccine candidate, to manage the manufacturing process during its Phase II clinical trials.

Vaccination 52

Vaccination Vaccine Development Clinical Trials 52

Pharmaceutical Technology

DECEMBER 2, 2022

India’s Central Drugs Standard Control Organisation (CDSCO) has granted approval for Bharat Biotech’s BBV154 vaccine for treating Covid-19. BBV154 is claimed to be the first intra-nasal vaccine for Covid-19 in the world.

Vaccination 217

Vaccination Vaccine Clinical Trials Clinical Trials 217

Pharmaceutical Technology

NOVEMBER 30, 2022

in a project agreement from the US government for developing self-amplifying RNA (saRNA) vaccine technology against advanced and emergent viral threats. Development of vaccines to Phase I trials under the five-year $59m prototype project comprises additional $28.4m in milestone payments.

Vaccination 147

Vaccination Vaccine Development Gene Therapy 147

Pharmaceutical Technology

JULY 6, 2022

The European Commission (EC) has granted approval for the expanded conditional marketing authorization (CMA) of Novavax’s Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), in the European Union (EU) for adolescents of the age 12 to 17 years. A protein-based vaccine, NVX-CoV2373 is made from the genetic sequence of the SARS-CoV-2 virus’ first strain.

Vaccination 264

Vaccination Vaccine Protein Clinical Trials 264

World of DTC Marketing

DECEMBER 9, 2020

Pfizer is having supplier issues, some people who received the vaccine are reporting side effects like Bell’s Palsy. In the meantime this administration is patting itself on the back for the quick development of vaccines. The post Vaccine issues already? There are 14 FDA inspectors to cover the whole country.

Vaccination 272

Vaccination Vaccine Pharmacy Pharma Companies 272

Pharmaceutical Technology

JUNE 24, 2022

Novavax has obtained emergency use authorization (EUA) for its Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), from the Taiwan Food and Drug Administration for use in people of the age 18 years and above. The protein-based vaccine is engineered from the genetic sequence of the SARS-CoV-2 virus’ initial strain.

Vaccination 263

Vaccination Vaccine Clinical Trials Clinical Trials 263

Drug Discovery World

APRIL 18, 2024

For the first time, a controlled human infection model for tuberculosis (TB) has been developed and could help with the future development of TB vaccines. The team states that it’s the first step towards establishing a challenge model that can be used to test new vaccines for TB.

Vaccination 52

Vaccination Vaccine Development Bacterium 52

pharmaphorum

MARCH 20, 2024

A highly anticipated phase 3 trial of a new tuberculosis vaccine developed by GSK has started in Africa, funded by the Gates MRI and Wellcome.

Vaccination 87

Vaccination Vaccine Trials Development 87

Pharmaceutical Technology

SEPTEMBER 5, 2022

The National Medical Products Administration of China (NMPA) has approved CanSino Biologics ’ (CanSinoBIO) recombinant Covid-19 vaccine (Adenovirus Type 5 Vector) for inhalation, Convidecia Air, as a booster. This vaccine leverages the same adenovirus vector technological platform as Convidecia, the intramuscular version.

Vaccination 264

Vaccination Vaccine Genetic Engineering Clinical Trials 264

Bio Pharma Dive

JANUARY 10, 2023

Moderna’s Stéphane Bancel and Pfizer’s Albert Bourla hinted Monday at greater dealmaking to come for their companies, while Gilead gave investors an update on an important cancer drug trial.

Trials 277

Trials Drug Trials Development Vaccination 277

Drug Discovery World

MAY 1, 2024

Our preclinical results suggest that our vaccines may significantly outperform them, to transform care for future cancer patients.” It will also support development of Infinitopes’ lead asset, a novel cancer vaccine called ITOP1, which is scheduled to commence a Phase I/IIa study in first line cancer patients in the third quarter of 2024.

Vaccination 59

Vaccination Vaccine Development Clinical Trials 59

Pharmaceutical Technology

AUGUST 17, 2022

On August 8, Pfizer and Valneva announced the initiation of a Phase III study with their Lyme disease vaccine , bringing the prospect of an injection to prevent the condition disease one step closer to reality. This means that the vaccine works against multiple serotypes of the disease, she explains. In June 2022, Pfizer acquired 8.1%

Vaccination 299

Vaccination Vaccine Bacteria Protein 299

Pharmaceutical Technology

AUGUST 2, 2022

Samsung Biologics and GreenLight Biosciences have completed the initial commercial-scale engineering run for their messenger ribonucleic acid (mRNA) Covid-19 vaccine under their manufacturing collaboration. Following the demonstration at Samsung, the clinical trial of GreenLight’s Covid-19 booster vaccine is anticipated to commence this year.

Engineer 262

Engineer Vaccination Vaccine Clinical Trials 262